We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+17.11%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$174M
AUM Growth
+$23.9M
Cap. Flow
+$13.2M
Cap. Flow %
7.62%
Top 10 Hldgs %
75.05%
Holding
53
New
3
Increased
5
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$17.2M
2
FHTX icon
Foghorn Therapeutics
FHTX
+$6.02M
3
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.47M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.24M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$309K

Top Sells

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$10M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$1.36M
3
EPZM
Epizyme, Inc
EPZM
+$835K
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$344K
5
VYGR icon
Voyager Therapeutics
VYGR
+$320K

Sector Composition

Rank Sector Weight
1 Healthcare 96.79%
2 Energy 1.15%
3 Consumer Staples 0.06%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$49.3M 28.39%
794,386
– –
BDSX icon
2
Biodesix
BDSX
$209M
$22.3M 12.83%
+55,254
New +$17.2M
AXDX
3
DELISTED
Accelerate Diagnostics
AXDX
$16.6M 9.58%
219,380
– –
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$10.5M 6.07%
58,644
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$7.69M 4.43%
80,200
+2,200
+3% +$212K
FHTX icon
6
Foghorn Therapeutics
FHTX
$305M
$6.37M 3.67%
+314,143
New +$6.02M
AWH
7
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$5.62M 3.24%
56,007
-150,000
-73% -$10M
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.38B
$5.45M 3.14%
102,000
– –
ALBO
9
DELISTED
Albireo Pharma Inc
ALBO
$3.45M 1.99%
92,000
+34,000
+59% +$1.24M
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.97M 1.71%
170,303
– –
BIIB icon
11
Biogen
BIIB
$30.4B
$2.96M 1.71%
12,100
+1,100
+10% +$284K
KPTI icon
12
Karyopharm Therapeutics
KPTI
$216M
$2.91M 1.68%
12,533
+1,333
+12% +$309K
UTHR icon
13
United Therapeutics
UTHR
$22.7B
$2.73M 1.57%
18,000
– –
BLUE
14
DELISTED
bluebird bio
BLUE
$2.68M 1.55%
4,786
+154
+3% +$97.6K
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$2.39M 1.38%
18,672
– –
MASI
16
DELISTED
Masimo
MASI
$2.15M 1.24%
8,000
– –
CCXI
17
DELISTED
ChemoCentryx, Inc.
CCXI
$1.86M 1.07%
30,000
– –
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.69M 0.97%
22,000
– –
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$1.6M 0.92%
55,127
– –
AMRN
20
Amarin Corp
AMRN
$292M
$1.47M 0.85%
15,000
– –
BIOR
21
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$1.33M 0.77%
+1,000
New +$1.47M
CORT icon
22
Corcept Therapeutics
CORT
$9.72B
$1.31M 0.75%
50,000
– –
ARVN icon
23
Arvinas
ARVN
$517M
$1.27M 0.73%
15,000
– –
STOK icon
24
Stoke Therapeutics
STOK
$1.81B
$1.24M 0.71%
20,000
– –
HROW icon
25
Harrow
HROW
$1.74B
$1.24M 0.71%
180,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Birchview Capital held 53 positions worth $174M, up 16% from $150M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Birchview Capital deployed $13.2M of net new capital in Q4 2020, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Biodesix: 55,254 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Aspira Women's Health Inc. Common Stock, an estimated $10M trimmed.

  • Birchview Capital's largest Q4 2020 buy was Biodesix: 55,254 shares worth $22.3M.
  • Birchview Capital added most to Albireo Pharma Inc in Q4 2020, an estimated $1.24M increase.
  • Birchview Capital's biggest Q4 2020 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $10M.
  • Birchview Capital fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $1.36M.
  • Birchview Capital's ten largest holdings make up 75% of its $174M portfolio in Q4 2020.
  • Birchview Capital opened 3 new positions and closed 5 in Q4 2020.
  • Birchview Capital's portfolio value rose 16% quarter-over-quarter to $174M.

Based on Birchview Capital's 13F filing for Q4 2020, filed 9 Feb 2021.